Author

E. Iwanowicz

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 3

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 3 Organism:human· 3 Research Focus:cancer & tumor microenvironment· 2 Assay:bulk RNA-seq· 1 Research Focus:cell signaling & trafficking· 1 Research Focus:cell type annotation· 1 Research Focus:differential expression· 1 Research Focus:drug response / drug discovery· 1

Frequent Co-Authors

E. M. J. Fennell· 2 shared L. M. Graves· 2 shared S. Lipkowitz· 2 shared Y. E. Greer· 2 shared B. Tang· 1 shared C. Annunziata· 1 shared D. Karanewsky· 1 shared D. Voeller· 1 shared

Activity by Year

2022-2022 · peak 3/yr

Co-Author Collaboration Network

10 top collaborators · 26 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersCancer Biology

E. M. J. Fennell

Mutual co-authors in cluster

Author profile →

3 papers

Recent·Most cited

SMALL MOLECULE CLPP AGONISTS INDUCE SENESCENCE AND ALTER TRAIL-MEDIATED APOPTOTIC RESPONSE OF TRIPLE-NEGATIVE BREAST CANCER CELLS

L. J. Aponte-Collazo, E. M. J. Fennell, M. P. East, T. S. K. Gilbert, P. R. Graves, H. Ashamalla, E. Iwanowicz, Y. E. Greer, S. Lipkowitz, L. M. Graves

This paper shows that ClpP activators induce senescence in triple-negative breast cancer cells and enhance their sensitivity to TRAIL-mediated apoptosis.

bioRxiv · Jul 11, 2022 · PreprintCancer Biology

Mitochondrial Matrix Protease ClpP Agonists inhibit Cancer Stem Cell Function in Breast Cancer Cells by Disrupting Mitochondrial Homeostasis

Y. E. Greer, L. Hernandez, E. M. J. Fennell, D. Voeller, R. Chari, S. F. Gilbert, B. Tang, M. Hafner, C. Annunziata, E. Iwanowicz, L. M. Graves, S. Lipkowitz

This study shows that ClpP agonists inhibit breast cancer stem cell function by disrupting mitochondrial homeostasis and multiple metabolic pathways.

bioRxiv · Mar 18, 2022Cancer Biology

The CIpP activator, TR-57, is highly effective as a single agent and in combination with venetoclax against CLL cells in vitro.

N. Fatima, Y. Shen, K. Crassini, E. Iwanowicz, H. Lang, D. Karanewsky, R. Christopherson, S. Mulligan, G. Best

This study shows TR-57 is effective as a single agent and in combination with venetoclax against CLL cells in vitro, regardless of TP53 aberrations.

bioRxiv · Mar 7, 2022Cancer Biology